WO2000037103A3 - Compounds for intracellular delivery of therapeutic moieties to nerve cells - Google Patents

Compounds for intracellular delivery of therapeutic moieties to nerve cells Download PDF

Info

Publication number
WO2000037103A3
WO2000037103A3 PCT/US1999/028211 US9928211W WO0037103A3 WO 2000037103 A3 WO2000037103 A3 WO 2000037103A3 US 9928211 W US9928211 W US 9928211W WO 0037103 A3 WO0037103 A3 WO 0037103A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
nerve cells
intracellular delivery
therapeutic moieties
compound
Prior art date
Application number
PCT/US1999/028211
Other languages
French (fr)
Other versions
WO2000037103A2 (en
Inventor
Robert R Webb
Constance A Mckee
Original Assignee
Xavos
Robert R Webb
Constance A Mckee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xavos, Robert R Webb, Constance A Mckee filed Critical Xavos
Priority to EP99960608A priority Critical patent/EP1140201B1/en
Priority to AU17468/00A priority patent/AU777207B2/en
Priority to CA002356454A priority patent/CA2356454A1/en
Priority to JP2000589213A priority patent/JP2002532560A/en
Priority to AT99960608T priority patent/ATE556721T1/en
Publication of WO2000037103A2 publication Critical patent/WO2000037103A2/en
Publication of WO2000037103A3 publication Critical patent/WO2000037103A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/21—Hydrocarbon

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A compound for delivering a non-cytotoxic therapeutic moiety into nerve cells, the compound having the general formula : B-L-TM where: B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell; TM is a therapeutic moiety which has a non-cytotoxic therapeutic effect when absorbed by a nerve cell; and L is a linker coupling B to TM.
PCT/US1999/028211 1998-12-21 1999-11-29 Compounds for intracellular delivery of therapeutic moieties to nerve cells WO2000037103A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP99960608A EP1140201B1 (en) 1998-12-21 1999-11-29 Compounds for intracellular delivery of therapeutic moieties to nerve cells
AU17468/00A AU777207B2 (en) 1998-12-21 1999-11-29 Compounds for intracellular delivery of therapeutic moieties to nerve cells
CA002356454A CA2356454A1 (en) 1998-12-21 1999-11-29 Compounds for intracellular delivery of therapeutic moieties to nerve cells
JP2000589213A JP2002532560A (en) 1998-12-21 1999-11-29 Compounds for intracellular delivery of therapeutic components to nerve cells
AT99960608T ATE556721T1 (en) 1998-12-21 1999-11-29 COMPOUNDS FOR INTRACELLURARY DELIVERY OF THERAPEUTIC UNITS TO NERVE CELLS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/217,037 1998-12-21
US09/217,037 US6652864B1 (en) 1998-12-21 1998-12-21 Compounds for intracellular delivery of therapeutic moieties to nerve cells

Publications (2)

Publication Number Publication Date
WO2000037103A2 WO2000037103A2 (en) 2000-06-29
WO2000037103A3 true WO2000037103A3 (en) 2000-10-19

Family

ID=22809430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/028211 WO2000037103A2 (en) 1998-12-21 1999-11-29 Compounds for intracellular delivery of therapeutic moieties to nerve cells

Country Status (7)

Country Link
US (5) US6652864B1 (en)
EP (1) EP1140201B1 (en)
JP (1) JP2002532560A (en)
AT (1) ATE556721T1 (en)
AU (1) AU777207B2 (en)
CA (1) CA2356454A1 (en)
WO (1) WO2000037103A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652864B1 (en) * 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2003020200A2 (en) 2000-11-16 2003-03-13 New River Pharmaceuticals Inc. A novel pharmaceutical compound and methods of making and using same
US20060280724A1 (en) * 2000-11-04 2006-12-14 Ferguson Ian A Identification of ligands that enable endocytosis, using in vivo manipulation of neuronal fibers
CA2436830A1 (en) * 2000-11-06 2002-06-20 Asilomar Pharmaceuticals, Inc. Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins
ES2373641T3 (en) * 2000-11-16 2012-02-07 Shire Llc A NEW PHARMACEUTICAL COMPOUND AND METHODS TO MANUFACTURE AND USE.
WO2002049672A2 (en) * 2000-12-21 2002-06-27 Mcgill University Conjugates of antibodies and anticancer drugs
US7338939B2 (en) 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
ES2500117T3 (en) 2002-02-22 2014-09-30 Shire Llc Novel sustained release pharmaceutical compounds to prevent the abuse of controlled substances
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
PT1575517E (en) 2002-12-24 2012-05-28 Rinat Neuroscience Corp Anti-ngf antibodies and methods using same
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
EP1675555A4 (en) 2003-09-30 2011-03-09 Shire Llc Pharmaceutical compositions for prevention of overdose or abuse
ITRM20030601A1 (en) 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
US20080233049A1 (en) * 2004-06-23 2008-09-25 Ian Andrew Ferguson Agents And Methods For Early Diagnosis And Monitoring Of Alzheimer's Disease And Other Neurological Disorders
ITRM20050290A1 (en) 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
US7662177B2 (en) 2006-04-12 2010-02-16 Bacoustics, Llc Apparatus and methods for pain relief using ultrasound waves in combination with cryogenic energy
PL2308514T3 (en) * 2007-03-23 2013-11-29 To Bbb Holding B V Conjugates for targeted drug delivery across the blood-brain barrier
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
AU2011336470B8 (en) 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
WO2020018700A1 (en) * 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
EP4048736A4 (en) * 2019-10-23 2023-11-01 Manzanita Pharmaceuticals, Inc. Neurotrophin receptor binding conjugate compositions, methods of use and methods of making thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007092A1 (en) * 1993-09-10 1995-03-16 The University Of Medicine And Dentistry Of New Jersey Blood-brain barrier transporters of neurological agents
WO1995032738A1 (en) * 1994-05-31 1995-12-07 Allergan, Inc. Modification of clostridial toxins for use as transport proteins
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5505931A (en) * 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
US5563250A (en) * 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
WO1997023608A1 (en) * 1995-12-22 1997-07-03 Chiron Corporation Compositions and methods for targeting gene delivery vehicles using covalently bound targeting elements
US5767288A (en) * 1996-01-05 1998-06-16 California Institute Of Technology Photolabile linkers and probes
US5833988A (en) * 1989-09-07 1998-11-10 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US554498A (en) * 1896-02-11 Bottle
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US5232695A (en) * 1987-12-23 1993-08-03 G. D. Searle & Co. Method of ameliorating herpes simplex virus infections using purified nerve growth factor
US5486599A (en) * 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
US5094848A (en) * 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
JP3032287B2 (en) 1989-12-11 2000-04-10 イムノメデイツクス・インコーポレイテツド Antibody targeting of diagnostic or therapeutic agents
US5948384A (en) 1990-09-14 1999-09-07 Syngenix Limited Particulate agents
WO1992011846A1 (en) 1991-01-07 1992-07-23 St George's Enterprises Limited Particulates
DE69231178T2 (en) 1991-08-30 2000-11-23 Syngenix Ltd NUCLEIC ACID AMPLIFICATION THROUGH POLYMERASE REACTION
DK0625195T3 (en) 1991-11-15 1999-08-30 Univ California Treatment of the central nervous system with genetically modified cells
EP0599303A3 (en) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5728803A (en) * 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
US7144983B1 (en) * 1997-02-03 2006-12-05 Genentech, Inc. Pantropic neurotrophic factors
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5990078A (en) * 1995-07-14 1999-11-23 The Trustees Of Columbia University In The City Of New York Means of increasing estrogen receptor levels in neural tissue
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
GB9525180D0 (en) * 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
US6406710B1 (en) * 1996-01-16 2002-06-18 Nikos Panayotatos Protein occlusion for delivery of small molecules
AU2242897A (en) * 1996-01-16 1997-08-11 Nikos Panayotatos Protein occlusion for delivery of small molecules
US5994317A (en) 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6197743B1 (en) * 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
US6486303B1 (en) * 1998-04-14 2002-11-26 University Of Medicine & Dentistry Of New Jersey Method for making hormone heterodimers
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
WO2000053236A2 (en) 1999-03-08 2000-09-14 Gerhart Graupner Methods and compositions for targeted drug delivery
WO2001091798A2 (en) 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563250A (en) * 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US5833988A (en) * 1989-09-07 1998-11-10 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5505931A (en) * 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
WO1995007092A1 (en) * 1993-09-10 1995-03-16 The University Of Medicine And Dentistry Of New Jersey Blood-brain barrier transporters of neurological agents
WO1995032738A1 (en) * 1994-05-31 1995-12-07 Allergan, Inc. Modification of clostridial toxins for use as transport proteins
WO1997023608A1 (en) * 1995-12-22 1997-07-03 Chiron Corporation Compositions and methods for targeting gene delivery vehicles using covalently bound targeting elements
US5767288A (en) * 1996-01-05 1998-06-16 California Institute Of Technology Photolabile linkers and probes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BINKLEY JONATHAN ET AL: "RNA ligands to human nerve growth factor.", NUCLEIC ACIDS RESEARCH 1995, vol. 23, no. 16, 1995, pages 3198 - 3205, XP002139707, ISSN: 0305-1048 *
KRAMER K ET AL: "Monoclonal antibody to human Trk-A: Diagnostic and therapeutic potential in neuroblastoma.", MEETING ON ADVANCES IN NEUROBLASTOMA RESEARCH;PHILADELPHIA, PENNSYLVANIA, USA; MAY 22-25, 1996, vol. 33, no. 12, October 1997 (1997-10-01), European Journal of Cancer Oct., 1997, pages 2090 - 2091, XP002139706, ISSN: 0959-8049 *
MALIARTCHOUK SERGEI ET AL: "Optimal nerve growth factor trophic signals mediated by synergy of TrkA and p75 receptor-specific ligands.", JOURNAL OF NEUROSCIENCE, vol. 17, no. 16, 1997, pages 6031 - 6037, XP002140658, ISSN: 0270-6474 *

Also Published As

Publication number Publication date
US7678378B2 (en) 2010-03-16
EP1140201A2 (en) 2001-10-10
US6887861B1 (en) 2005-05-03
AU1746800A (en) 2000-07-12
CA2356454A1 (en) 2000-06-29
US20100266492A1 (en) 2010-10-21
US20090124547A1 (en) 2009-05-14
US8138155B2 (en) 2012-03-20
AU777207B2 (en) 2004-10-07
EP1140201B1 (en) 2012-05-09
US6652864B1 (en) 2003-11-25
US7718605B2 (en) 2010-05-18
WO2000037103A2 (en) 2000-06-29
ATE556721T1 (en) 2012-05-15
JP2002532560A (en) 2002-10-02
US20050260211A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
WO2000037103A3 (en) Compounds for intracellular delivery of therapeutic moieties to nerve cells
WO2001010842A3 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
EP1128453A3 (en) Secondary battery using a radical compound as active electrode material
WO2000071518A3 (en) Heterocyclic analgesic compounds and their use
AU5865500A (en) Platinum-ruthenium-palladium alloys for use as a fuel cell catalyst
WO2002062766A3 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
AU5557800A (en) Thieno- and furopyrimidine derivatives as a2a-receptor antagonists
EP0995742A4 (en) Sulfonamide compounds and medicinal use thereof
ZA200205095B (en) A diesel fuel having a very high iso-paraffin to normal paraffin mole ratio.
WO1997009036A3 (en) Improved pharmaceutical ion exchange resin composition
CA2370147A1 (en) Piperidine-indole compounds having 5-ht6 affinity
BR9713694A (en) Absorbent article with three-dimensional longitudinal booms
WO2001047479A3 (en) Skin moisturizing composition
WO1999039740A3 (en) Sensitizing cells to compounds using lipid-mediated gene and compound delivery
AU764280C (en) Process for the preparation of pellets with a content of up to 90 wt. per cent of a pharmaceutical active ingredient
WO2002096903A3 (en) Chemical derivatives and the use thereof as an anti-telomerase agent
CA2386936A1 (en) Antiviral compositions for tissue paper
AU2002231374A1 (en) Synergistic biocidal oxidant composition
CA2402390A1 (en) Process for the preparation of pyrimidone derivatives with antifungal activity
EP1046691A3 (en) Use of high hydroxyl compounds for water sensitive hot melt adhesives
AU2001267720A1 (en) A unit for enabling two reactant materials to be mixed
CA2412594A1 (en) Pyrazino[1',2':1,6]pyrido[3-4-5] indole derivatives
AU2002229611A1 (en) Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells
TW357085B (en) Sustained release excipient
CA2330217A1 (en) Therapeutic agent for a cancer and method of screening the same and health-care auxiliary food

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 17468

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 17468/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2356454

Country of ref document: CA

Ref country code: CA

Ref document number: 2356454

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 589213

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999960608

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999960608

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 17468/00

Country of ref document: AU